Disposition of guanethidine during chronic oral therapy. 1979

J H Hengstmann, and F C Falkner

The plasma level and urinary excretion rate of guanethidine have been measured in 30 patients during oral maintenance therapy, and in 5 patients following discontinuous of therapy. A significant correlation was found between the daily average urinary excretion and the maintenance dose, although wide interindividual variation was noted among patients maintained on the same dose. A statistically significant correlation was also observed between the area under the plasma level curve during the dose interval and the oral maintenance dose. After discontinuation of chronic therapy, the half-life of 1.5 days of the initial phase of elimination was essentially in agreement with the half-life of almost 2 days determined in acute studies. In addition, a second phase of elimination with a half-life of 4 to 8 days was observed.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D006145 Guanethidine An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. ((2-Hexahydro-1(2H)-azocinyl)ethyl)guanidine,Guanethidine Monosulfate,Guanethidine Sulfate,Guanethidine Sulfate (1:1),Guanethidine Sulfate (1:2),Guanethidine Sulfate (2:1),Guanethidine Sulfate (2:1), 14C-Labeled,Ismelin,Isobarin,Octadine,Oktadin,Monosulfate, Guanethidine,Sulfate, Guanethidine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

J H Hengstmann, and F C Falkner
October 1969, Klinicheskaia meditsina,
J H Hengstmann, and F C Falkner
September 1970, Zeitschrift fur Kreislaufforschung,
J H Hengstmann, and F C Falkner
January 1975, Journal of clinical pharmacology,
J H Hengstmann, and F C Falkner
August 1976, The Journal of family practice,
J H Hengstmann, and F C Falkner
January 1982, European journal of clinical pharmacology,
J H Hengstmann, and F C Falkner
October 1977, British journal of clinical pharmacology,
J H Hengstmann, and F C Falkner
April 1990, Cardiovascular drugs and therapy,
J H Hengstmann, and F C Falkner
July 1960, Deutsche medizinische Wochenschrift (1946),
Copied contents to your clipboard!